|
Sarilumab Clinical Trials
7 actively recruiting trials across 6 locations
No change since May 2026
Also known as: Kevzara, Kevzara®, REGN88, REGN88SAR153191, SAR153191
Pipeline
Phase 2: 3Phase 3: 1Phase 1/2: 3
Top Sponsors
- Regeneron Pharmaceuticals5
- University of Nebraska1
- NYU Langone Health1
Indications
- Cancer6
- Fallopian Tube Cancer2
- Primary Peritoneal Cancer2
- Endometrial Cancer2
- Ovarian Cancer2
Birmingham, Alabama2 trials
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
The University of Alabama at Birmingham
Phase 2
Goodyear, Arizona1 trial
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Cancer Treatment Centers of America, Phoenix
Phase 2
Duarte, California1 trial
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
City of Hope Comprehensive Cancer Center
Phase 1/2
Los Angeles, California1 trial
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
The Angeles Clinic at Cedars Sinai
Phase 2
Palo Alto, California1 trial
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Stanford University Medical Center - Blake Wilbur Drive
Phase 1/2
Omaha, Nebraska1 trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
University of Nebraska Medical Center
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.